X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

Content Team by Content Team
27th March 2023
in FDA Approvals, News

The European Medicines Agency (EMA) has released a paper summarizing its Regulatory Science Strategy (RSS) mid-point achievements through 2025. Originally released in March 2020, the strategy outlines a five-year goal for advancing regulatory science.

Regulatory science belongs to the scientific disciplines that are used to evaluate the quality, safety, and efficacy of pharmaceutical goods. According to the EMA, these assist in the development of regulatory standards and tools.

Results for the top five human suggestions projected to deliver the most substantial change across the five-year strategy are included. These are the results of a stakeholder engagement process with the EMA’s scientific bodies, stakeholders, and EU regulatory partners.

  • Some areas have seen progress, including:
  • Promoting clinical trial innovation.
  • Encouragement of the use of high-quality, real-world data in strategic planning.
  • Helping to ensure the readiness of health technology assessment bodies (HTA) and downstream decision-making for novel medications.
  • Helping to advance precision medicine.

According to Emer Cooke, EMA’s Executive Director, the achievements mentioned in this report illustrate that they have made significant progress in strengthening regulatory science to construct a more adaptive regulatory system that supports innovation.

The regulatory agency stated that the policy was driven by the increased rate of innovation in recent years. As a result, regulators needed to be ready to facilitate the development and evaluation of increasingly complex medications that provide healthcare solutions through convergent and varied technologies.

The industry’s pressures during the COVID-19 pandemic emphasized the significance of quick, close engagement of investors and collaborators involved in pharmaceutical development. This need was one of the strategy’s guiding concepts, as per EMA.

According to Cooke, they will look for opportunities to accelerate the delivery of the Regulatory Science Plan to 2025, as well as the broader European pharmaceutical agencies network strategy to 2025, as they emerge from a long period of business continuity. This effort will be critical in evolving the network’s potential to engage with and facilitate innovative research and technology within the current pharmaceutical gamut, and also paving the way for the legislative review.

After the strategy’s completion in 2026, a comprehensive report on it will be published.

Previous Post

AADC Inadequacy To Be Handled By A Novel Gene Therapy

Next Post

Nasal Spray Shows Its Effect Against New COVID Variants

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
U.S. FDA Approves DARZALEX Split-Dosing Regimen
Drug Development

EMA Keeping A Close Watch On Critical Medicine Shortages

22nd March 2023
Next Post

Nasal Spray Shows Its Effect Against New COVID Variants

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In